Monoclonal antibody + Tyrosine kinase inhibitorPhase 3 trialInvestigational
Pembrolizumab + Lenvatinib
How it works
Blocks PD-1 and the VEGF pathway in cancer cells, preventing them from growing and dividing.
Cancer types
Melanoma— All patients
Efficacy
Studies show that around 50% of patients achieved an objective response, with a median progression-free survival of approximately 14.9 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.